Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Specialists

Neither a doctor nor a teaching hospital

Research payments

$875,010

35 payments

Through program year 2025, Boston Specialists is reported as receiving $875,010 in research payments, across 35 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $219,052 14
2024 Research $259,659 6
2023 Research $235,720 12
2022 Research $160,579 3

Breakdown

Who paid Research payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $403,291 8 payments
  2. QOL Medical, LLC $125,074 5 payments
  3. Celgene Corporation $102,488 4 payments
  4. E.R. Squibb & Sons, L.L.C. $85,006 4 payments
  5. Sanofi US Services Inc. $82,603 9 payments
  6. Novartis Pharmaceuticals Corporation $68,548 3 payments
  7. GlaxoSmithKline, LLC. $8,000 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) $224,163 3 payments
  2. A Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) $123,617 3 payments
  3. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $82,603 9 payments
  4. QOL Fructan $81,025 4 payments
  5. A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $68,548 3 payments
  6. Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $67,741 2 payments
  7. A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis $55,511 2 payments
  8. A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $54,671 1 payment
  9. Ssdxa-14 $44,049 1 payment
  10. Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti $34,747 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record